Tumour deposits in colorectal carcinoma are associated with immune evasion and dose-dependent adverse prognosis beyond nodal status
Tumor deposits beyond standard lymph nodes predict worse outcomes and immune-evasion patterns, informing future cancer staging and immunotherapy decisions.
In 845 CRC resections, tumor deposit burden showed dose-dependent adverse survival beyond standard nodal staging, with immune-evasive signatures (reduced CD8+, upregulated PD-L1) in TD-positive tumors. Findings support TD burden incorporation into future CRC staging paradigms and identify a potential biomarker for immunotherapy eligibility.
What the study was
- Study design
- Single-institution retrospective cohort with immune profiling (IHC)
- Population
- CRC resection patients, Beth Israel Deaconess / Harvard, 2007–2015
- Sample size
- 845
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- British Journal of Cancer
Why it surfaced
n=845; immune profiling; supports TD burden in CRC staging — implementable through standard IHC pathology workflow.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.